Strs Ohio Acquires Shares of 16,445 Jazz Pharmaceuticals PLC $JAZZ

Strs Ohio acquired a new stake in Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor acquired 16,445 shares of the specialty pharmaceutical company’s stock, valued at approximately $2,042,000.

A number of other hedge funds also recently bought and sold shares of the business. Cetera Investment Advisers acquired a new stake in shares of Jazz Pharmaceuticals during the 4th quarter worth approximately $1,243,000. Deutsche Bank AG increased its holdings in shares of Jazz Pharmaceuticals by 4.0% during the 4th quarter. Deutsche Bank AG now owns 16,012 shares of the specialty pharmaceutical company’s stock worth $1,972,000 after buying an additional 609 shares during the last quarter. Focus Partners Wealth acquired a new stake in shares of Jazz Pharmaceuticals during the 4th quarter worth approximately $551,000. Nuveen Asset Management LLC increased its holdings in shares of Jazz Pharmaceuticals by 1.8% during the 4th quarter. Nuveen Asset Management LLC now owns 468,346 shares of the specialty pharmaceutical company’s stock worth $57,677,000 after buying an additional 8,448 shares during the last quarter. Finally, Nomura Holdings Inc. increased its holdings in shares of Jazz Pharmaceuticals by 218.3% during the 4th quarter. Nomura Holdings Inc. now owns 8,022 shares of the specialty pharmaceutical company’s stock worth $988,000 after buying an additional 5,502 shares during the last quarter. Institutional investors and hedge funds own 89.14% of the company’s stock.

Insider Activity

In other news, Director Bruce C. Cozadd sold 6,000 shares of the business’s stock in a transaction dated Tuesday, September 2nd. The shares were sold at an average price of $128.62, for a total transaction of $771,720.00. Following the transaction, the director directly owned 429,973 shares in the company, valued at $55,303,127.26. The trade was a 1.38% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. 4.30% of the stock is currently owned by company insiders.

Analyst Ratings Changes

JAZZ has been the subject of a number of recent analyst reports. Royal Bank Of Canada raised their price target on shares of Jazz Pharmaceuticals from $145.00 to $151.00 and gave the stock an “outperform” rating in a report on Thursday, August 28th. Deutsche Bank Aktiengesellschaft began coverage on shares of Jazz Pharmaceuticals in a report on Tuesday, July 15th. They set a “buy” rating and a $152.00 price target for the company. Truist Financial increased their price objective on shares of Jazz Pharmaceuticals from $200.00 to $205.00 and gave the stock a “buy” rating in a research report on Thursday, August 28th. The Goldman Sachs Group increased their price objective on shares of Jazz Pharmaceuticals from $162.00 to $185.00 and gave the stock a “buy” rating in a research report on Friday, August 29th. Finally, Zacks Research raised shares of Jazz Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research report on Friday, August 15th. Fourteen analysts have rated the stock with a Buy rating and two have issued a Hold rating to the stock. According to MarketBeat, Jazz Pharmaceuticals presently has an average rating of “Moderate Buy” and an average target price of $178.67.

Jazz Pharmaceuticals Price Performance

Jazz Pharmaceuticals stock opened at $125.22 on Tuesday. Jazz Pharmaceuticals PLC has a 12-month low of $95.49 and a 12-month high of $148.06. The stock has a market cap of $7.60 billion, a P/E ratio of -18.61, a price-to-earnings-growth ratio of 7.82 and a beta of 0.24. The company has a current ratio of 1.62, a quick ratio of 1.37 and a debt-to-equity ratio of 1.17. The company has a fifty day simple moving average of $118.95 and a 200-day simple moving average of $116.22.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last announced its quarterly earnings results on Tuesday, August 5th. The specialty pharmaceutical company reported ($8.25) earnings per share for the quarter, missing analysts’ consensus estimates of ($5.61) by ($2.64). The company had revenue of $1.05 billion during the quarter, compared to analysts’ expectations of $1.05 billion. Jazz Pharmaceuticals had a negative net margin of 9.91% and a positive return on equity of 5.02%. Jazz Pharmaceuticals’s revenue was up 2.1% on a year-over-year basis. During the same period last year, the firm earned $5.30 earnings per share. Jazz Pharmaceuticals has set its FY 2025 guidance at 4.800-5.600 EPS. Equities analysts expect that Jazz Pharmaceuticals PLC will post 16.96 EPS for the current fiscal year.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.